Research Analysts Offer Predictions for NTLA Q3 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Research analysts at Leerink Partnrs lifted their Q3 2025 EPS estimates for shares of Intellia Therapeutics in a note issued to investors on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.09) per share for the quarter, up from their previous forecast of ($1.10). The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share. Leerink Partnrs also issued estimates for Intellia Therapeutics' Q4 2025 earnings at ($1.28) EPS.

NTLA has been the subject of several other reports. Wedbush reaffirmed a "neutral" rating and issued a $7.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 16th. Chardan Capital reaffirmed a "buy" rating and issued a $68.00 target price on shares of Intellia Therapeutics in a research report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 16th. Guggenheim dropped their target price on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Finally, Citigroup dropped their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Intellia Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $33.37.

Intellia Therapeutics Trading Up 1.9%

NASDAQ:NTLA opened at $12.06 on Monday. The company has a 50-day moving average price of $9.46 and a 200-day moving average price of $9.32. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $27.42. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -2.31 and a beta of 2.21.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. Intellia Therapeutics had a negative net margin of 1,154.10% and a negative return on equity of 56.06%. The firm's revenue for the quarter was down 42.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.12) EPS.

Institutional Trading of Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in Intellia Therapeutics during the 4th quarter valued at about $25,000. Sterling Capital Management LLC grew its stake in shares of Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after acquiring an additional 2,867 shares during the period. Resona Asset Management Co. Ltd. bought a new stake in shares of Intellia Therapeutics in the fourth quarter worth approximately $43,000. Northwestern Mutual Wealth Management Co. grew its stake in shares of Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock worth $33,000 after acquiring an additional 1,655 shares during the period. Finally, Harbour Investments Inc. grew its stake in shares of Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after acquiring an additional 2,264 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.